Sign up to save your data!
Some tips to help get started:
Processing...
There are 420 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
420 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible patients are adults with metastatic or unresectable advanced solid tumors—including ovarian, endometrial, triple-negative breast, and non-small cell lung cancers—who have received prior systemic therapy. The investigational treatment is GEN1107, an intravenous antibody-drug conjugate targeting PTK7, which delivers a cytotoxic payload to PTK7-expressing tumor cells.
ClinicalTrials.gov ID: NCT06171789
HealthScout AI summary: Adults with advanced or metastatic mesothelin-expressing cancers (including ovarian cancer and NSCLC) who have progressed after standard therapies or have no suitable standard treatment receive ZW171, a bispecific antibody targeting mesothelin on tumor cells and CD3 on T cells to promote T cell-mediated cytotoxicity.
ClinicalTrials.gov ID: NCT06523803
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
HealthScout AI summary: This study enrolls adults with unresectable, locally advanced, or metastatic antigen-rich solid tumors—including TMB-H, MSI-H/dMMR, virally associated, metastatic colorectal, triple negative breast, platinum-resistant ovarian, metastatic castration-resistant prostate, and NSCLC—who lack standard treatment options. Patients receive STAR0602 (invikafusp alfa), a bifunctional bispecific antibody that selectively activates and expands Vβ6/Vβ10 T cell subsets to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05592626
HealthScout AI summary: This trial enrolls adults with advanced or metastatic colorectal, pancreatic, gastric/gastroesophageal junction, or lung cancers that have progressed after standard therapy, testing PF-08046050 (SGN-CEACAM5C), an anti-CEACAM5 antibody-drug conjugate linked to a topoisomerase I inhibitor, as monotherapy and in combination with bevacizumab. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT06131840
HealthScout AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
HealthScout AI summary: This trial enrolls adults with advanced/metastatic renal cell carcinoma, non-small cell lung cancer, melanoma, gastric cancer, or colorectal cancer who have received multiple prior lines of therapy, and treats them with HFB200603, a BTLA (B and T lymphocyte attenuator) antagonist monoclonal antibody, as monotherapy or in combination with the anti-PD-1 antibody tislelizumab. Patients must have measurable disease, ECOG 0-1, and a tumor site amenable to biopsy.
ClinicalTrials.gov ID: NCT05789069
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741
HealthScout AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
HealthScout AI summary: Adults with advanced or metastatic solid tumors harboring specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) are eligible for treatment with LY4066434, a highly selective small molecule pan-KRAS inhibitor, given as monotherapy or in combination with standard chemotherapy or immunotherapy regimens. Active CNS metastases and significant unresolved toxicities are exclusion criteria.
ClinicalTrials.gov ID: NCT06607185
